Skip to main content

Table 1 Demographic information on the two study cohorts

From: Metabolic profiling reveals interleukin-17A monoclonal antibody treatment ameliorate lipids metabolism with the potentiality to reduce cardiovascular risk in psoriasis patients

 

Cohort 1

Cohort 2

CON (n = 28)

PSO (n = 28)

IXE (n = 28)

CON (n = 17)

PSO

(n = 17)

PC (n = 17)

CV (n = 10)

Male/Female

19/9

19/9

19/9

13/4

15/2

14/3

8/2

Age (years)

45 ± 11.6

45 ± 11.5

45 ± 11.5

62 ± 6.6

60 ± 7.1

63 ± 7.3

68 ± 14.3

BMI

24.1 ± 2.8

24.9 ± 2.8

26.1 ± 3.1

23.9 ± 2.4

24.1 ± 3.1

24.9 ± 3.9

23.3 ± 2.4

PASI

n/a

24.4 ± 8.7

0.4 ± 0.3

n/a

21.70 ± 12.2

16.87 ± 15.99

n/a

  1. Values are reported as mean ± SD
  2. BMI body mass index, PASI psoriasis area and severity index, CON group of healthy controls, PSO group of psoriasis patients, IXE group of ixekizumab-treated psoriasis patients, PC group of psoriasis patients with coronary heart disease, CV group of coronary heart disease patients without psoriasis
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X